Eikon Therapeutics, Inc.(EIKN)
$6.67+0.54 (+8.81%)
EIKN
Eikon Therapeutics, Inc. financials statements
$6.67
At close:+0.54 (+8.81%)
Eikon Therapeutics, Inc. (EIKN) Ratios
32 Followers
Eikon Therapeutics, Inc. Ratios
EIKN's free cash flow for Q2 2026 was $-65.21M. For the 2026 fiscal year, EIKN's free cash flow was decreased by $-251.00K and operating cash flow was $-64.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 6.34 |
| Quick Ratio | 6.34 |
| Cash Ratio | 1.91 |
| Solvency Ratio | -0.20 |
| Operating Cash Flow Ratio | -3.43 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -1.12B |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.43 |
| Debt-to-Equity Ratio | -0.29 |
| Debt-to-Capital Ratio | -0.41 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -0.68 |
| Debt Service Coverage Ratio | -357.51 |
| Interest Coverage Ratio | -404.95 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 4.77 |
| Net Debt to EBITDA | -0.51 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 95.66% |
| Return on Assets (ROA) | -54.52% |
| Return on Equity (ROE) | 36.89% |
| Return on Capital Employed (ROCE) | -62.80% |
| Return on Invested Capital (ROIC) | -61.65% |
| Return on Tangible Assets | -54.52% |
| Earnings Yield | -39.93% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 35.50 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | -10.28 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 10.28 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -3.48 |
| Free Cash Flow Per Share | -4.35 |
| Dividend Paid and CapEx Coverage Ratio | -4.03 |
| Capital Expenditure Coverage Ratio | -4.03 |
| Operating Cash Flow Coverage Ratio | -0.73 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -28.97% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -2.44 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -0.92 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.45 |
| Price-to-Operating Cash Flow Ratio | -4.31 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -3.22 |
| Enterprise Value | 964.50M |
| EV to EBITDA | -3.22 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -4.10 |
| EV to Operating Cash Flow | -5.12 |
| Tangible Book Value Per Share | -16.24 |
| Shareholders’ Equity Per Share | -16.24 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -5.99 |
| Tax Burden | 1.00 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.58 |
Currency in USD
